Estados Unidos - inglés - NLM (National Library of Medicine)

virtus pharmaceuticals llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g

Estados Unidos - inglés - NLM (National Library of Medicine)

cardinal health - sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

noripharma sdn. bhd. - citric acid monohydrate; potassium citrate -

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma manufacturing sdn bhd - citric acid,monohydrate; potassium citrate -

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - glycine; citric acid monohydrate; glucose anhydrous; potassium citrate; potassium phosphate monobasic; sodium chloride - oral solution/suspension - glycine amino acid-glycine active 6.18 g/sa; citric acid monohydrate acid-general active 0.48 g/sa; glucose anhydrous carbohydrate active 44.61 g/sa; potassium citrate mineral-potassium active 0.12 g/sa; potassium phosphate monobasic mineral-potassium active 4.08 g/sa; sodium chloride mineral-sodium-salt active 8.58 g/sa - nutrition & metabolism - calf | cat | dog | horse foal | lamb | pigs | beef calf | bitch | boar | bovine | calf - poddy | calf - preweaning | calf - suck - dehydration | diarrhoea | scours | absorptive | acute diarrhoea | acute intestinal catarrh | avian blackhead | bacterial enteritis | blackhead | chronic diarrhoea | coccidiosis | dietary factors | dietary upset | enteritis | feed conversion | flatulance | fluid loss | gastro-intestinal | gram negative bacteria | growth rate | k88+ serotypes of e.coli | nesting diarrhoea | non-specific irritants | poisoning | postweaning scours | prophylactic | scours | selenium responsive scours | streptomycin sensitive bacteri | sulphadiazine sensitive bacter | sulphonamide sensitive bacteri | trichomoniasis | trimethoprim sensitive bacteri | white scours

Estados Unidos - inglés - NLM (National Library of Medicine)

cypress pharmaceutical, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g - cytra-k crystals is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. cytra-k crystals is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. cytra-k crystals alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium cit

Estados Unidos - inglés - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets is contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. - in patients with peptic ulcer disease because of its ulcerogenic potential. - in patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). the ability of potassium citrate extended-release tablet to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. moreover, the rise in urinary ph resulting from potassium citrate extended-release tablet therapy might promote further bacterial growth. - in patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. animal reproduction studies have not been conducted. it is also not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. potassium citrate should be given to a pregnant woman only if clearly needed. the normal potassium ion content of human milk is about 13 meq/l. it is not known if potassium citrate has an effect on this content. potassium citrate should be given to a woman who is breast feeding only if clearly needed. safety and effectiveness in children have not been established.

Estados Unidos - inglés - NLM (National Library of Medicine)

major® pharmaceuticals - sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

Estados Unidos - inglés - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage.this product is highly palatable, pleasant tasting,and tolerable, even when a administered for long periods. contraindicated in patients with sodium-restr

Estados Unidos - inglés - NLM (National Library of Medicine)

strides pharma inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)] . potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)] . potassium citrate extended-release tablets are contraindicated: • in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal